Search
Now showing items 1-8 of 8
Pay for your Facebook posts?
(Economic Times, 2019-02-14)
Old drugs in a new avatar
(DNA, 2019-02-20)
Did India’s price control policy for coronary stents create unintended consequences?
(Social Science & Medicine, 2020)
In February 2017, India capped the retail price of coronary stents and restricted the channel margin to bring Percutaneous Transluminal Coronary Angioplasty (PTCA) procedure, which uses coronary stents, within reach of ...
From courts to markets: new evidence on enforcement of pharmaceutical bans in India
(Social Science & Medicine, 2019)
Regulatory enforcement of product safety standards given health concerns, whether it is in romaine lettuce, smartphones or cars, is emerging to be a challenge for global public health. This is particularly true for developing ...
The Welfare Implications of Patent Protection, Pricing and Licensing in the Indian Oral Anti-Diabetic Market
(Indian Institute of Management Ahmedabad, 2013)
We evaluate the welfare effects of differential pricing, voluntary licensing, and compulsory licensing in the Indian market for oral anti-diabetic (OAD) drugs. This market includes a new class of molecules called DPP-4 ...
Pandemics and technology engagement: new evidence from m-Health intervention during COVID-19 in India
(Wiley, 2022-07-12)
Information provision for social welfare via cheap technological media is now a widely available tool used by policymakers. Often, however, an ample supply of information does not translate into high consumption of information ...
Did the COVID-19 pandemic propel usage of AI in pharmaceutical innovation? New evidence from patenting data
(Elsevier, 2024-01-01)
It is now much discussed that Artificial Intelligence (AI) as a General-Purpose Technology (GPT) can resolve the
efficiency problems of industries, including in pharmaceutical markets where productivity challenges continue ...